Scientific deep-dive

Protein Targets and the Lab Panel

At least 1.2 g of protein per kg daily, 0.3–0.4 g/kg per meal, and a short lab panel: vitamin D, B12, iron studies, folate and zinc, plus thiamin in high-risk patients. The upper protein target excludes chronic kidney disease.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·3 citations

“Eat more protein and get your bloods done” is the standard advice, and without numbers it gives you nothing to act on. Two 2026 reviews put numbers to it: a floor of 1.2 g protein for every kilogram you weigh, divided so each meal carries its share, plus a short laboratory panel.[1][2] Here are those figures and the one exclusion attached to them.

The protein targets

Protein targets proposed in a 2026 dietitian-led framework for people on incretin therapy.
TargetAmount
Daily intake≥1.2 g/kg body weight
Upper range, appropriate adults without CKDup to 1.6 g/kg
Per meal~0.3–0.4 g/kg
Leucine per meal~2.5–3 g
The upper target explicitly excludes chronic kidney disease, and that exclusion matters for many people on these drugs. Reduced kidney function is common in this group, and higher protein intake is not neutral when it is present. Our kidneys article covers why. If you do not know your kidney function, that is the test to do before raising protein, not after.

The per-meal figure matters more than people expect. Muscle protein synthesis responds to a threshold dose at a sitting rather than to a daily total, which is why the framework specifies both. On a drug that suppresses appetite, hitting a per-meal target across fewer, smaller meals is hard, and that is the practical reason protein tends to be the macronutrient that slips. A protein-dense snack is one way to make it up; low-calorie snacks on a GLP-1 ranks the options. An eating window cuts the number of meals further; see intermittent fasting on a GLP-1.

The laboratory panel

The proposed panel is short and specific: vitamin D, B12, iron studies, folate and zinc, plus thiamin in high-risk patients.[1] A few online GLP-1 practices build testing into the price. GoodLife Health’s membership includes four lab panels a year, and EverPrime includes metabolic labs every six months with each compounded GLP-1 plan. Ask whether those panels cover this list before relying on them. At Base1 Health, a Texas practice, the blood test comes before the prescription: a doctor looks at the results, then decides whether a GLP-1 is right for you.

Each is there for a reason connected to how these drugs work rather than to general wellness testing. Reduced intake and reduced dietary diversity affect all of them; nausea and vomiting affect thiamin acutely; and baseline inadequacy is already common in people with obesity before any drug is involved, which the reviews note explicitly.[1][2] Lab panels sold with peptides are a different matter, covered in peptide blood work.

What runs low in practice, with figures from a large dataset, is covered separately in eating too little on a GLP-1. This panel is the counterpart, covering what to measure.

Vitamin D, B12, iron studies, folate and zinc, plus thiamin in high-risk patients.

Energy floors

The same framework proposes pragmatic energy floors, meaning a minimum daily intake below which micronutrient adequacy becomes very difficult regardless of what you choose to eat.[1] The point holds even without a specific number. Below a certain intake, no amount of good food selection compensates, because there is not enough food.

This is where the appetite suppression that makes the drug work becomes the thing to manage. Appetite is a poor guide to adequacy on these drugs by design, which is the argument for eating to a plan rather than to hunger.

Vitamin D, and why the number moves on its own

One panel value needs explaining before anyone reacts to it. In 195 people with obesity who completed an eight-week low-calorie diet before being randomized in a weight-maintenance trial, that diet raised serum vitamin D by about 12 to 13 nmol/L in both women and men, with no supplement involved.[3]

Vitamin D is fat-soluble, and fat tissue holds onto it. Carrying more fat means more of the body’s vitamin D is sequestered where a blood test cannot see it, so the serum number reads low. Lose fat and it is released back into circulation, and the number rises, even though intake and sun exposure have not changed.

That mechanism explains the study’s most striking finding, and explains it away. Women who went on to lose more weight over the following year had lower vitamin D at the start: 54 nmol/L, against 70 in women who regained. Read as a predictor, that says poor vitamin D status forecasts success, which makes no sense. Read as a fat compartment, it says those women had more fat to begin with, and more to lose.

The practical consequence is that a rising vitamin D level during weight loss is not evidence that anything is being done right, and a low one at the start is not necessarily a deficiency to correct. It is a measurement whose denominator is changing underneath it. Whether to supplement is a question for the clinician reading the whole panel, and this particular number should not drive it on its own.

The same trial found the additional rise with further weight loss only in women, which the authors report without explaining, and we cannot explain it either.

What kind of evidence this is

The two sources behind these targets are narrative reviews proposing a framework, not randomized trials testing one. The protein targets are guideline-informed extrapolations into a new context rather than figures validated in people taking these drugs.

That is a real limitation, but it does not make them useless. There is no trial establishing the right protein intake on a GLP-1, and there may never be one; in its absence, an explicit number derived from established nutrition guidance is more useful than “eat more protein”. Our lean mass article covers the outcome these targets are aimed at, and the one intervention with randomized support behind it: resistance training.

One thing these targets do not address: they assume the protein is available at the amount stated, and where it comes from changes how hard that is. If you eat little or no animal protein, the daily total matters more than it does otherwise and the per-meal response is weaker (see plant-based protein on a GLP-1 for what the trials measured). Creatine is the supplement most often suggested alongside a protein target; what the evidence supports for creatine on a GLP-1 is narrower than the marketing, and no trial has tested it in anyone taking these drugs.

Frequently Asked Questions

A 2026 framework sets a floor of 1.2 g for every kilogram you weigh, rising to 1.6 g/kg for suitable adults who do not have chronic kidney disease, with roughly 0.3 to 0.4 g/kg at each sitting. These are guideline-informed targets rather than figures validated in a trial of people taking these drugs.
Because muscle protein synthesis responds to a threshold dose at a sitting rather than to a daily total. On a drug that suppresses appetite, reaching that threshold across fewer and smaller meals is the practical difficulty.
No. The upper target explicitly excludes chronic kidney disease, which is common in this population. If you do not know your kidney function, establish it before increasing protein, not afterward.
The proposed panel is vitamin D, B12, iron studies, folate and zinc, with thiamin added for high-risk patients. It is short, and each item relates to reduced intake, reduced dietary diversity, or the gastrointestinal effects of the drugs.
They come from narrative reviews proposing a framework rather than from trials testing one. No trial has established the correct protein intake on a GLP-1. An explicit number extrapolated from established nutrition guidance is more useful than 'eat more protein', but it is not validated.

References

  1. 1.Arslan S, et al. Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation Clinical Nutrition ESPEN. 2026. PMID: 42036071.
  2. 2.Simancas-Racines D, Campuzano-Donoso M, Rossetti G, et al. Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework Obesity Pillars. 2026. PMID: 42382663.
  3. 3.Holt R, Holt J, Jorsal MJ, et al. Weight Loss Induces Changes in Vitamin D Status in Women With Obesity But Not in Men: A Randomized Clinical Trial The Journal of Clinical Endocrinology and Metabolism. 2025. PMID: 39530599.

Plant-Based Protein on a GLP-1: What Closes the Gap, and Why the Drug Widens It

Across a full day at high protein intake a vegan diet matched an omnivorous one for muscle. Per meal, an omnivorous meal produced about 47% more muscle protein synthesis than a vegan one, and a GLP-1 works against the intake that closes the gap.

7 min read

Nutrition Drinks Alongside a GLP-1

A real-world study associated nutrition drinks with more fat loss and a better fat-to-lean ratio. The strongest effects were among people who complied, which is a compliance finding wearing a product's clothes.

5 min read

Creatine on a GLP-1: The Trial Nobody Has Run

No completed trial has tested creatine in people taking a GLP‑1. The 2026 review of lean-mass preservation classes it as indirect evidence, and the lean-mass number most often quoted for it is one creatine inflates.

6 min read

The Diet Advice Nobody Has Tested

Everyone on these drugs is told to hit a protein target, drink more, add fiber. A review of 16 randomized trials of these drugs given alongside dietary guidance concluded that evidence on the optimal nutritional approach remains limited.

7 min read

Gymnema Sylvestre: A Meta-Analysis With No Control Group

The meta-analysis behind gymnema's blood-sugar claim pooled 10 studies and 419 people and reported large effects at p < 0.0001. They were calculated by comparing participants after treatment with the same participants at baseline, with heterogeneity up to 99%.

5 min read

GLP-1s During Ramadan: What the Four Studies Actually Tested

Four studies exist on taking a GLP‑1 through Ramadan and all four enrolled people with type 2 diabetes. Both randomized trials compared against a sulfonylurea, a drug class whose defining hazard is low blood sugar.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

From $149/mo + membership

Get started →
Read full review →
8.5

Gala

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →